New injection GenSci120 takes first step toward taming autoimmune disease
NCT ID NCT06827457
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a single injection of GenSci120 in 58 healthy adults to see if it is safe and how the body processes it. The drug aims to control the immune system, which could one day help people with autoimmune diseases. Because this is a Phase 1 study, it only looks at safety and dosing, not yet whether it works for any specific condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GenSci120
What this could lead to
If successful, this could lead to a new treatment option for autoimmune diseases by controlling the immune system.
What could go wrong
This is a very early Phase 1 trial in only 58 healthy people, so it cannot yet show if the drug works for any disease. Safety and dosing are the only goals here.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huashan Hospital
Shanghai, Shanghai Municipality, 20040, China